<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343048">
  <stage>Registered</stage>
  <submitdate>10/06/2011</submitdate>
  <approvaldate>10/06/2011</approvaldate>
  <actrnumber>ACTRN12611000602921</actrnumber>
  <trial_identification>
    <studytitle>Glycaemic effects of Omega-3 (GEO) - Can omega-3 (fish oil) supplementation improve insulin sensitivity in middle aged males?</studytitle>
    <scientifictitle>Can dietary supplementation with n-3 long chain polyunsaturated fatty acids compared with placebo improve insulin sensitivity in overweight middle aged males?</scientifictitle>
    <utrn>U1111-1122-0964</utrn>
    <trialacronym>GEO</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Insulin resistance</healthcondition>
    <healthcondition>Overweight</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>n-3 long chain polyunsaturated fatty acids from marine source at a dose of 1.4g/day for 8 weeks given in the form of oral capsules. There will be a 4 week washout period between swapping treatments.</interventions>
    <comparator>Placebo oil capsule containing a vegetable oil without n-3 LC PUFAs, likely safflower oil, given for 8 weeks in the form of oral capsules. There will be a 4 week washout period before swapping treatments.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Insulin resistance as measured by Matsuda index from oral glucose tolerance test</outcome>
      <timepoint>After 8 weeks of taking the n-3 PUFA oil or placebo oil</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Physiological assessments
body mass index, body composition by DEXA scan</outcome>
      <timepoint>After 8 weeks of taking the n-3 PUFA oil or placebo oil</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum lipids</outcome>
      <timepoint>After 8 weeks of taking the n-3 PUFA oil or placebo oil</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Carotid Artery intimal thickness, measured using ultrasound scan.</outcome>
      <timepoint>After 8 weeks of taking the n-3 PUFA oil or placebo oil</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum inflammatory markers</outcome>
      <timepoint>After 8 weeks of taking the n-3 PUFA oil or placebo oil</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>General Wellness by SF-36 Quality of Life Questionnaire</outcome>
      <timepoint>After 8 weeks of taking the n-3 PUFA oil or placebo oil</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum adipokine levels - adiponectin and leptin</outcome>
      <timepoint>After 8 weeks of taking the n-3 PUFA oil or placebo oil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Body Mass index 25-30 kg/m2</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>54</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prexisting medical conditions under treatment
Hypertension
Allergy to fish or seafood
Using prescription pharmaceuticals, neutraceuticals, antioxidants or other supplements
Smoker
Planning to change level of exercise or fish intake during the course of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by computer</concealment>
    <sequence>Computerised random number lists</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Auckland, Liggins Institute</primarysponsorname>
    <primarysponsoraddress>2-6 Park Avenue
Grafton
Auckland 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>The University of Auckland, Liggins Institute</fundingname>
      <fundingaddress>2-6 Park Avenue
Grafton
Auckland 1142</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Omega-3 supplements are very commonly used by people in the community for a multitude of purposes. Recent studies have suggested a way that they could improve the way the body processes sugar and in doing so reduce the risk of developing diabetes, and maybe help to treat it. However this has not been adequately tested in humans. This study aims to test this in an at risk group, middle aged males.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>14/06/2011</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Ben Albert</name>
      <address>Liggins Institute, University of Auckland
2-6 Park Rd
Grafton
Auckland 1142</address>
      <phone>+64 9 9231151</phone>
      <fax />
      <email>b.albert@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Ben Albert</name>
      <address>Liggins Institute, University of Auckland
2-6 Park Rd
Grafton
Auckland 1142</address>
      <phone>+64 9 9231151</phone>
      <fax />
      <email>b.albert@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Benjamin Albert</name>
      <address>Liggins Institute, University of Auckland
2-6 Park Rd
Grafton
Auckland 1142</address>
      <phone>+64 9 9231151</phone>
      <fax />
      <email>b.albert@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>